FDA approves GE’s SenoClaire
The FDA has approved SenoClaire, GE’s breast tomosynthesis device that was developed in collaboration with Massachusetts General Hospital.
SenoClaire uses a short sweep of low-dose x-ray around the breast, taking nine exposures in a “step-and-shoot” method, according to GE.
There are currently 180 units installed across Europe, Australia, Latin America, Southeast Asia and the Middle East.